Altimmune Scheduled to Report Q3 2026 Earnings Results
Altimmune (NASDAQ: ALT) is set to release its third-quarter earnings report on Thursday, November 12th, prior to the market opening. Investors are closely monitoring the upcoming announcement following recent volatility regarding the company's drug candidate, pemvidutide. The consensus earnings per share (EPS) estimate for the quarter stands at -$0.14. Market sentiment surrounding the report appears mixed, as EPS estimates have undergone significant revisions over the last three months, including two upward and four downward adjustments.
Tickers: $ALT